From: Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Gene
No. of patients
No. of mutations
%
KRAS
32
1
3
BRAF
0
CDH1
22
2
9
